...
search icon
cldi-img

Calidi Biotherapeutics Inc., Common Stock

CLDI

ASQ

$0.326

-$0.03

(-8.43%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$11.00M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
541.98K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.06
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.34 L
$3.89 H
$0.326

About Calidi Biotherapeutics Inc., Common Stock

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCLDISectorS&P500
1-Week Return-5.2%1.08%1.06%
1-Month Return-28.54%1.11%6.17%
3-Month Return-58.48%-9.16%6.82%
6-Month Return-83.01%-7.29%-0.94%
1-Year Return-84%-8.72%11.83%
3-Year Return32700%5.18%49.19%
5-Year Return32700%30.45%86.63%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-449.00K45.00K--[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":10.02,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-94.00K274.00K1.26M1.53M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":6.12,"profit":true},{"date":"2022-12-31","value":17.85,"profit":true},{"date":"2023-12-31","value":81.82,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit-355.00K(229.00K)(1.26M)-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-64.51,"profit":false},{"date":"2023-12-31","value":-353.8,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin-79.06%(508.89%)--[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-643.64,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses6.77M1.78M22.90M28.99M21.78M[{"date":"2020-12-31","value":23.36,"profit":true},{"date":"2021-12-31","value":6.15,"profit":true},{"date":"2022-12-31","value":78.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":75.11,"profit":true}]
Operating Income(6.77M)(1.78M)(23.13M)(28.99M)(21.78M)[{"date":"2020-12-31","value":-677300000,"profit":false},{"date":"2021-12-31","value":-178170000,"profit":false},{"date":"2022-12-31","value":-2312800000,"profit":false},{"date":"2023-12-31","value":-2899200000,"profit":false},{"date":"2024-12-31","value":-2177600000,"profit":false}]
Total Non-Operating Income/Expense(1.32M)(1.05M)(2.41M)(3.96M)(1.35M)[{"date":"2020-12-31","value":-132300000,"profit":false},{"date":"2021-12-31","value":-105400000,"profit":false},{"date":"2022-12-31","value":-241000000,"profit":false},{"date":"2023-12-31","value":-395700000,"profit":false},{"date":"2024-12-31","value":-135200000,"profit":false}]
Pre-Tax Income(7.93M)3.39M(25.42M)(29.20M)(22.20M)[{"date":"2020-12-31","value":-234.24,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-750.45,"profit":false},{"date":"2023-12-31","value":-862.18,"profit":false},{"date":"2024-12-31","value":-655.35,"profit":false}]
Income Taxes4.00K11.00K11.00K16.00K14.00K[{"date":"2020-12-31","value":25,"profit":true},{"date":"2021-12-31","value":68.75,"profit":true},{"date":"2022-12-31","value":68.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":87.5,"profit":true}]
Income After Taxes(7.94M)3.38M(25.43M)(29.22M)(22.21M)[{"date":"2020-12-31","value":-235.12,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-753.23,"profit":false},{"date":"2023-12-31","value":-865.47,"profit":false},{"date":"2024-12-31","value":-657.9,"profit":false}]
Income From Continuous Operations(7.94M)(10.93M)(21.16M)(29.22M)(22.21M)[{"date":"2020-12-31","value":-793700000,"profit":false},{"date":"2021-12-31","value":-1093300000,"profit":false},{"date":"2022-12-31","value":-2116000000,"profit":false},{"date":"2023-12-31","value":-2921600000,"profit":false},{"date":"2024-12-31","value":-2220900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(7.94M)(10.93M)(25.43M)(29.22M)(22.14M)[{"date":"2020-12-31","value":-793700000,"profit":false},{"date":"2021-12-31","value":-1093300000,"profit":false},{"date":"2022-12-31","value":-2542700000,"profit":false},{"date":"2023-12-31","value":-2921600000,"profit":false},{"date":"2024-12-31","value":-2214300000,"profit":false}]
EPS (Diluted)-0.12(0.05)(3.30)(2.52)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-41.67,"profit":false},{"date":"2023-12-31","value":-2753.42,"profit":false},{"date":"2024-12-31","value":-2100,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CLDI
Cash Ratio 1.95
Current Ratio 2.12

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CLDI
ROA (LTM) -111.74%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CLDI
Debt Ratio Lower is generally better. Negative is bad. 0.52
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.46

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CLDI
Trailing PE NM
Forward PE NM
P/S (TTM) 50.83
P/B 1.63
Price/FCF NM
EV/R 49.42
EV/Ebitda NM

FAQs

What is Calidi Biotherapeutics Inc. share price today?

Calidi Biotherapeutics Inc. (CLDI) share price today is $0.326

Can Indians buy Calidi Biotherapeutics Inc. shares?

Yes, Indians can buy shares of Calidi Biotherapeutics Inc. (CLDI) on Vested. To buy Calidi Biotherapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CLDI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Calidi Biotherapeutics Inc. be purchased?

Yes, you can purchase fractional shares of Calidi Biotherapeutics Inc. (CLDI) via the Vested app. You can start investing in Calidi Biotherapeutics Inc. (CLDI) with a minimum investment of $1.

How to invest in Calidi Biotherapeutics Inc. shares from India?

You can invest in shares of Calidi Biotherapeutics Inc. (CLDI) via Vested in three simple steps:

  • Click on Sign Up or Invest in CLDI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Calidi Biotherapeutics Inc. shares
What is Calidi Biotherapeutics Inc. 52-week high and low stock price?

The 52-week high price of Calidi Biotherapeutics Inc. (CLDI) is $3.89. The 52-week low price of Calidi Biotherapeutics Inc. (CLDI) is $0.34.

What is Calidi Biotherapeutics Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Calidi Biotherapeutics Inc. (CLDI) is 1.63

What is the Market Cap of Calidi Biotherapeutics Inc.?

The market capitalization of Calidi Biotherapeutics Inc. (CLDI) is $11.00M

What is Calidi Biotherapeutics Inc.’s stock symbol?

The stock symbol (or ticker) of Calidi Biotherapeutics Inc. is CLDI

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top